



Update

### ❖ New Drug Information

- **Forfivo™ XL (bupropion extended-release):** The Food and Drug Administration (FDA) approved IntelGenx's high dose bupropion for the treatment of depression. The manufacturer is looking for a marketing partner and is not expected to launch the product until mid-2012.
- **Xarelto® (rivaroxaban):** In early November, Janssen/Johnson & Johnson received FDA approval for a second indication. Xarelto is now approved for the prevention of stroke in patients with nonvalvular atrial fibrillation in 15 mg and 20 mg strengths.
- **arterolane maleate and piperazine phosphate:** Ranbaxy received FDA approval for their combination malaria treatment.
- **Intermezzo® (zolpidem sublingual):** Transcept Pharmaceuticals received FDA approval for their sublingual formulation of zolpidem after receiving two complete response letters. Intermezzo is approved for the treatment of insomnia associated with middle-of-the-night waking followed by difficulty returning to sleep.

### ❖ Generic Drug Information

- **Kadian® (morphine sulfate extended-release):** Watson launched their generic version of Actavis' long-acting pain reliever Kadian.
- **Lipitor® (atorvastatin):** Ranbaxy launched their generic version of Pfizer's Lipitor on December 1, 2011. Watson has also launched their authorized generic product. Atorvastatin is available in 10 mg, 20 mg, 40 mg and 80 mg strengths and Ranbaxy will hold 180-day marketing exclusivity. According to Drug Topics, Lipitor was the second largest drug by annual U.S. retail sales accounting for \$5.3 billion. This marks the largest generic launch in U.S. history.

Some or all of the information contained in this document may contain confidential and/or proprietary information and should be treated accordingly. Prime Therapeutics LLC does not warrant that the information contained herein is free from error and it should be used only as an informational guide. Nothing herein represents the promotion of any drugs or manufacturers by Prime Therapeutics LLC.

Prime Therapeutics LLC does not warrant that the information contained herein is free from error and it should be used only as an informational guide. Nothing herein represents the promotion of any drugs or manufacturers by Prime Therapeutics LLC and no conclusions of formulary status shall be inferred from any discussion herein.